Track topics on Twitter Track topics that are important to you
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...
Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.
Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during progressive forms of the disease. Although development of multifocal inflammatory lesions is the unde...
In findings that show the effectiveness of a new strategy for treating multiple sclerosis (MS), researchers are reporting positive results from three large, international, multicenter Phase III clinic...
A clinical trial led by Imperial College London has revealed the potential of a risky new therapy to stop the progression of multiple sclerosis. Worldwide, there are 2.3 million people with multiple s...
More frequent use of health care in patients with multiple sclerosis than in controls in the 5 years before a first demyelinating event, according to health administrative data, suggests the existence...
Apitope is developing therapeutic peptides to induce suppression of autoimmune responses towards self-antigens. Their recent phase IIa trial has revealed promising results for the treatment of multipl...
A Phase III trial of ocrelizumab in primary-progressive multiple sclerosis and two Phase III trials of ocrelizumab in relapsing-remitting multiple sclerosis have demonstrated efficacy with treatment.
Thursday, February 9th 2017 at 5:00pm UTC NEWTOWN, Pa.–(BUSINESS WIRE)– Helius Medical Technologies, Inc. (TSX: HSM, HSM.S, OTCQB: HSDT) (« Helius ») is pleased to anno...
Multiple Sclerosis Current and Future PlayersSummaryGlobalData has released its pharma report, Multiple Sclerosis Current and Future Players. The report is a vital source of uptodate information wit...
Corrigendum to Ragheb, S et al. (2011). Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid Multiple Sclerosis Journal 17(07) 819-829. [DOI: 10.1177/1352458511398887].
It is well known that multiple sclerosis (MS) patients are very sensitive to heat events. However, how MS patients respond to the significant temperature difference between the high- and low-latitude ...
Previous studies have suggested a relationship between neuroanatomical and neurofunctional hippocampal alterations and episodic memory impairments in multiple sclerosis (MS) patients.
To investigate levels of oxysterols in healthy control (HC) and multiple sclerosis (MS) patients and their interdependence with demographic, clinical characteristics, and cholesterol biomarkers.
Neuroimaging studies have used magnetic resonance imaging-derived methods to assess brain volume loss in multiple sclerosis (MS) as a reliable measure of diffuse tissue damage.